<DOC>
	<DOCNO>NCT00746486</DOCNO>
	<brief_summary>The study aim compare efficacy tolerability combination therapy ursodeoxycholic acid ( 12-16 mg/kg body weight ( BW ) /d ) plus budesonide ( 9 mg/d ) vs. ursodeoxycholic acid ( 12-16 mg/kg BW/d ) plus placebo treatment PBC . Depending ALT value 6 mg/d budesonide allow . The study population patient PBC risk disease progression . It assume combination therapy result decrease treatment failures 3 year treatment .</brief_summary>
	<brief_title>Ursodeoxycholic Acid Plus Budesonide Versus Ursodeoxycholic Acid Alone Primary Biliary Cirrhosis ( PBC )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>1 . Signed informed consent 2 . Age ≥ 18 year 3 . UDCA treatment least 6 month prior inclusion 4 . Liver biopsy compatible PBC 5 . Liver biopsy perform within last 6 month prior inclusion 6 . PBC patient risk disease progression base one follow criterion : Serum alkaline phosphatase ≥ 3 time upper limit normal time since diagnosis PBC ALT ≥ 2 time upper limit normal Total Bilirubin ≥ 1.0 mg/dl ( ≥ 17 µmol/L ) Moderate severe periportal periseptal lymphocytic interface hepatitis Periportal portal fibrosis numerous septum ( Ludwig stage III ) without cirrhosis 7 . Type 2 antimitochondrial antibody &gt; 1:40 direct immunofluorescence 8 . Women childbearing potential apply appropriate contraceptive method , e.g. , hormonal contraception , intrauterine device ( IUD ) , doublebarrier method contraception ( e.g. , use condom spermicide ) , partner undergone vasectomy subject monogamous relationship . The investigator responsible determine whether subject adequate birth control study participation 1 . Histologically proven cirrhosis 2 . Positive Hepatitis B C serology 3 . Positive HIV serology 4 . Primary Sclerosing Cholangitis 5 . Wilson'sDisease 6 . Celiac Disease ( blood test and/or oesophagogastroduodenoscopy histological examination perform ) 7. α1antiTrypsindeficiency 8 . Haemochromatosis 9 . AutoimmuneHepatitis ( AIH ; define Alvarez score &gt; 15 without treatment ≥ 17 treatment ) ; Note : PBC/AIH overlap disease , treat insufficiently UDCA monotherapy may enrol 10 . Treatment follow drug within last 3 month prior inclusion : colchicine , corticosteroid , azathioprine immunosuppressive drug ( e.g . cyclosporine , methotrexate ) , chlorambucil , Dpenicillamine , fibrates , antihyperlipidemic drug 11 . Treatment ketoconazole CYP3A inhibitor within last 4 week baseline ; rifampicin ( 600 mg/d ) allow treat pruritus baseline 12 . Sonographic endoscopic sign portal hypertension 13 . Ascites history ascites 14 . Hepatic encephalopathy history hepatic encephalopathy 15 . Total bilirubin &gt; 3.0 mg/dl ( &gt; 50 µmol/L ) 16 . Albumin &lt; 36 g/L 17 . Prothrombin ratio &lt; 70 % 18 . Platelet count &lt; 135.000/mm3 19 . Osteoporosis proven bone densitometry 20 . Diabetes mellitus , define BGlucose &gt; 125 mg/dl empty stomach ( even control ) 21 . Hypertension , define persistent raise blood pressure &gt; 140/90 mmHg 22 . Suspected noncompliance patient ( suspected difficulty comply study period 36 month ) 23 . Severe comorbidity substantially reduce life expectancy 24 . Known intolerance/hypersensitivity/resistance study drug drug similar chemical structure pharmacological profile 25 . Existing intended pregnancy breastfeed 26 . Participation another clinical trial within last 30 day , simultaneous participation another clinical trial , previous participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>